

Condensed Consolidated Interim Financial Statements (Unaudited)

Expressed in Canadian Dollars, unless otherwise noted

For the Three and Nine Months Ended September 30, 2023 and 2022

Table of Contents

| CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION | |
|--|---|
| CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS | |
| CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) | |
| CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS | |
| NOTE 1 - NATURE OF OPERATIONS AND GOING CONCERN | 2 |
| NOTE 2 - BASIS OF PREPARATION AND PRESENTATION, STATEMENT OF COMPLIANCE | 2 |
| NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES | |
| NOTE 4 - PREPAID EXPENSES AND DEPOSITS | 3 |
| NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES | 3 |
| NOTE 6 - SHARE CAPITAL | |
| NOTE 7 - SHARE-BASED PAYMENTS | 5 |
| NOTE 8 - RELATED PARTY TRANSACTIONS AND BALANCES | 7 |
| NOTE 9 - FINANCIAL INSTRUMENTS | |
| NOTE 10 - SEGMENT REPORTING | 9 |
| NOTE 11 - EVENTS AETED DEDODTING DEDIOD | |

Condensed Consolidated Interim Statements of Financial Position

As of September 30, 2023 and December 31, 2022

Unaudited - Expressed in Canadian Dollars

| As at | Notes | | September 30, 2023 | | December 31, 2022 |
|---|-------|----|-----------------------|----|----------------------|
| ASSETS | | | | | |
| Current | | | | | |
| Cash | | \$ | 6,972 | \$ | 232,402 |
| Receivables and advances | | | 30,184 | | 22,719 |
| Share subscriptions receivable | 6 | | - | | 75,000 |
| Prepaid expenses and deposits | 4 | | 10,682 | | 10,428 |
| TOTAL ASSETS | | \$ | 47,838 | \$ | 340,549 |
| LIABILITIES | | | | | |
| Current liabilities | | | | | |
| Accounts payables and accrued liabilities | 5 | | 1,220,555 | | 641.349 |
| Loans and borrowings | | | 65,562 | | 60,133 |
| Share subscriptions payable | | | 10,000 | | - |
| TOTAL LIABILITIES | | \$ | 1,296,117 | \$ | 701,482 |
| SHAREHOLDERS' DEFICIT | | | | | |
| Share capital | 6 | \$ | 23,694,382 | Ś | 23,594,542 |
| Contributed surplus | | • | 428,088 | · | 428,088 |
| Share-based payments and warrants reserve | 6,7 | | 886,908 | | 1,029,048 |
| Accumulated deficit | • | | (26,257,657) | | (25,412,611) |
| TOTAL SHAREHOLDERS' DEFICIT | | \$ | (1,248,279) | \$ | (360,933) |
| TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT | | \$ | 47,838 | \$ | 340,549 |

Events after reporting period (Note 11)
Approved on behalf of the Board of Directors on November 28, 2023

| "Douglas Fulcher" | "Kevin Milledge" |
|-------------------|------------------|
| Director | Director |

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

For the Three and Nine months Ended September 30, 2023 and 2022 Unaudited - Expressed in Canadian Dollars except number of shares

| | | Three months ended September 30: | | Nine months er | nded | September 30: | |
|--|-------|----------------------------------|-------------|-----------------|-------------------|---------------|-------------|
| | Notes | | 2023 | 2022 | 2023 | | 2022 |
| Expenses | | | | | | | |
| Exploration and evaluation | | \$ | - | \$ - | \$ - | \$ | 2,746 |
| General and administration | 8 | | 99,315 | 110,777 | 338,854 | | 316,438 |
| Professional and consulting fees | 8 | | 306,334 | 129,436 | 648,234 | | 443,412 |
| Share-based payments | 7 | | 17,600 | 120,208 | 236,000 | | 168,300 |
| Total expenses | | \$ | (423,249) | \$ (360,421) | \$ (1,223,088) | \$ | (930,896) |
| Operating loss | | \$ | (423,249) | \$ (360,421) | \$ (1,223,088) | \$ | (930,896) |
| Other income (expenses) | | | | | | | |
| Net financing cost | 6 | | (9,247) | (5,986) | (33,150) | | (15,548) |
| Foreign exchange gain (loss) | | | (551) | (424) | (1,158) | | (1,304) |
| Other expenses | | | - | (8) | - | | (25,008) |
| Net loss and comprehensive loss | | \$ | (433,047) | \$ (366,839) | \$ (1,257,396) | \$ | (972,756) |
| Basic and diluted loss per common share | | \$ | (0.00) | \$ (0.00) | \$ (0.01) | \$ | (0.01) |
| Weighted average number of common shares outstanding – basic and diluted | | | 194,581,868 | 179,539,431 | 194,276,080 | | 179,539,431 |

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficit) For the Nine Months Ended September 30, 2023 and 2022

Unaudited - Expressed in Canadian Dollars except number of shares

| | Notes | Share capital | Contributed surplus | Share-based payments and warrants reserve | Accumulated Deficit | Total shareholders' equity |
|--|-------|------------------|------------------------|--|------------------------|----------------------------------|
| Balance as of December 31, 2021 | | \$ 22,865,481 | \$ 66,955 | \$ 1,895,581 | \$ (24,797,246) | \$ 30,771 |
| Share based payments | 7(a) | - | - | 168,300 | - | 168,300 |
| Transfer of share-based payments expired | | - | - | (1,219,500) | 1,219,500 | - |
| Loss for the period | | - | - | - | (972,756) | (972,756) |
| Balance as of September 30, 2023 | | \$ 22,865,481 | \$ 66,955 | \$ 844,381 | \$ (24,550,502) | \$ (773,685) |
| Balance as of December 31, 2022 | | \$ 23,594,542 | \$ 428,088 | \$ 1,029,048 | \$ (25,412,611) | \$ (360,933) |
| Shares issued in private placement | 6(a) | 99,840 | - | 24,960 | - | 124,800 |
| Share based payments | 7(a) | - | - | 236,000 | - | 236,000 |
| Warrant modification | 6(b) | - | - | 9,250 | - | 9,250 |
| Transfer of share-based payments expired | | - | - | (412,350) | 412,350 | - |
| Net loss for the period | | - | - | - | (1,257,396) | (1,257,396) |
| Balance as of September 30, 2023 | | \$ 23,694,382 | \$ 428,088 | \$ 886,908 | \$ (26,257,657) | \$ (1,248,279) |

Condensed Consolidated Interim Statements of Cash Flows For the Nine Months Ended September 30, 2023 and 2022 Unaudited - Expressed in Canadian Dollars

| For the nine months ended: | September 30, 2023 | September 30, 2022 |
|--|-----------------------|-----------------------|
| Cash (used in) provided by: | | |
| OPERATING ACTIVITIES | | |
| Net loss | \$ (1,257,396) | \$ (972,756) |
| Non-cash items: | | |
| Share-based payments | 236,000 | 168,300 |
| Other expenses | - | 25,000 |
| Net financing cost | 33,150 | 15,548 |
| Foreign exchange loss (gain) | 1,158 | - |
| Changes in non-cash working capital items | | |
| Receivables and advances | (7,465) | 60,681 |
| Prepaid expenses and deposits | (254) | 60,330 |
| Accounts payable and accrued liabilities | 559,577 | (149,013) |
| Net cash used in operating activities | \$ (435,230) | \$ (791,910) |
| FINANCING ACTIVITIES | | |
| Advance for private placement | \$ 10,000 | \$ 399,955 |
| Proceeds from private placement, net of share issuance | 100 000 | |
| costs | 199,800 | - |
| Net cash provided by financing activities | \$ 209,800 | \$ 399,955 |
| Net increase (decrease) in cash in the period | \$ (225,430) | \$ (391,955) |
| Cash – opening balance | \$ 232,402 | \$ 685,108 |
| Cash – closing balance | \$ 6,972 | \$ 293,153 |

Notes to Condensed Consolidated Interim Financial Statements For the Three and Nine months Ended September 30, 2023 and 2022

Unaudited - Expressed in Canadian Dollars except otherwise noted

NOTE 1 - NATURE OF OPERATIONS AND GOING CONCERN

One World Lithium Inc., together with its subsidiary (collectively referred to as the "Company") was incorporated under the laws of the province of British Columbia on November 9, 1982. The Company is focused on the acquisition, exploration and development of lithium resource properties and a new lithium separation extraction technology. The Company is considered to be in the exploration stage and early development of its separation technology. The Company's head office and records offices are located at Suite 615, 800 West Pender Street, Vancouver, British Columbia, V6C 2V6. On January 19, 2018, the Company changed its name to One World Lithium Inc. to align with its primary exploration and evaluation asset and the trading symbol on the CSE was changed to OWLI. On March 7, 2019, the Company also began trading on the OTCQB Venture Market under the trading symbol OWRDF.

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") on a going concern basis, which contemplates the realization of assets and discharge of liabilities at their carrying values in the ordinary course of operations for the foreseeable future rather than through the process of forced liquidation.

During the nine months ended September 30, 2023, the Company generated a net loss of \$1,257,396 and cash used in operating activities of \$435,230. As at September 30, 2023, the Company had an accumulated deficit of \$26,257,657 and a working capital deficit of \$1,248,279. As a result, the Company may not have sufficient capital to fund its current planned operations for the foreseeable future.

These condensed consolidated interim financial statements do not include any adjustments to the classification and amounts of assets and liabilities that may be required should the Company be unable to continue as a going concern. Different bases of measurement may be appropriate if the Company is not expected to continue operations for the foreseeable future. The Company's continuing operations as intended are dependent upon its ability to identify, evaluate and negotiate the acquisition of, participation in or interest in new properties, assets or business opportunities, as well as the successful results from exploration activities, development of its lithium separation technology and its ability to attain profitable operations and generate funds therefrom, and raise equity capital or obtain the necessary financing sufficient to meet current and future obligations. These conditions indicate the existence of material uncertainties that may cast significant doubt about the Company's ability to continue as a going concern. Although the Company has been successful at raising funds in the past through the issuance of securities, it is uncertain whether it will be successful in doing so in the future.

NOTE 2 - BASIS OF PREPARATION AND PRESENTATION, STATEMENT OF COMPLIANCE

These condensed consolidated interim financial statements for the three and nine months ended September 30, 2023 have been prepared in accordance with IAS 34 Interim Financial Reporting, and should be read in conjunction with the Company's last annual consolidated financial statements as at and for the year ended December 31, 2022 ('last annual financial statements'). They do not include all of the information required for a complete set of financial statements prepared in accordance with IFRS. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company's consolidated financial position and performance since the last annual financial statements.

These condensed consolidated interim financial statements include the accounts of the Company and Lithium Investments Ltd., its wholly-owned subsidiary, a Canadian company.

These condensed consolidated interim financial statements were authorized for issue by the Company's board of directors on November 28, 2023.

Critical accounting judgments and estimates

The preparation of condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

Notes to Condensed Consolidated Interim Financial Statements For the Three and Nine months Ended September 30, 2023 and 2022

Unaudited - Expressed in Canadian Dollars except otherwise noted

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods.

Management notes no critical judgments exercised in the application of accounting policies and estimates having the most significant effects on the amounts recognized in these condensed consolidated interim financial statements.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

The accounting policies applied in these condensed consolidated interim financial statements are the same as those applied in the Company's consolidated financial statements as at and for the year ended December 31, 2022.

NOTE 4 - PREPAID EXPENSES AND DEPOSITS

| | September 30, 2023 | December 31, 2022 |
|-------------------------------------|--------------------|-------------------|
| Prepaid consulting fees | \$ - | \$ 2,630 |
| Prepaid advertising and promotion | 1,875 | 1,250 |
| Other prepaid expenses | 8,807 | 6,548 |
| Total prepaid expenses and deposits | \$ 10,682 | \$ 10,428 |

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

| | September 30, 2023 | December 31, 2022 |
|--|---------------------------|-------------------|
| Trade payables and accrued liabilities | \$ 707,440 | \$ 324,082 |
| Part XII.6 tax payable | 289,829 | 271,581 |
| Due to related parties (Note 8) | 223,286 | 45,686 |
| Total accounts payable and accrued liabilities | \$ 1,220,555 | \$ 641,349 |

NOTE 6 - SHARE CAPITAL

a) Common shares

Authorized: unlimited common shares without par value

| | Number of Shares | Amount |
|--|-------------------------|------------------|
| Balance, December 31, 2021 | 179,539,431 | \$ 22,865,481 |
| Common shares upon private placement, net of issuance costs (i) | 14,581,220 | 729,061 |
| Balance, December 31, 2022 | 194,120,651 | \$ 23,594,542 |
| Common shares upon private placement, net of issuance costs (ii) | 2,496,000 | 99,840 |
| Balance, September 30, 2023 | 196,616,651 | \$ 23,694,382 |

(i) On December 20, 2022, the Company closed its non-brokered private placement. The Company received a total of \$729,061 in cash proceeds through the issuance of 14,581,220 units at a price of \$0.05 per Unit. Of the \$729,061 total proceeds, \$34,260 was received in the prior year and was previously reported as a share subscription payable as at December 31, 2021. Furthermore, \$75,000 of the proceeds were uncollected as at December 31, 2022 and are presented as a share subscription receivable as at December 31, 2022, which was collected during the three months ended March 31, 2023.

Each Unit consists of one common share of the Company and one non-transferable common share purchase warrant. The Company incurred \$nil of share issuance costs in connection with the private placement.

Notes to Condensed Consolidated Interim Financial Statements For the Three and Nine months Ended September 30, 2023 and 2022

Unaudited - Expressed in Canadian Dollars except otherwise noted

A total of 14,581,220 warrants (each a "Warrant") were issued in connection with the private placement. Each Warrant will entitle the holder to purchase one Common Share at a price of \$0.08 for a period of 36 months from the closing of the offering. As the fair value of the Company's common shares on closing was greater than the consideration received on the units subscribed, no residual amount existed, and the warrants were valued at \$Nil. All securities are subject to a four month and one day hold from the closing date.

(ii) On September 14, 2023, the Company closed the first tranche of its non-brokered private placement (the "Offering"). The Company received a total of \$124,800 in cash proceeds through the issuance of 2,496,000 Units at a price of \$0.05 per Unit. Each Unit consists of one common share of the Company and one non-transferable common share purchase warrant (each a "Warrant"). The Company incurred \$nil of share issuance costs in connection with the private placement.

A total of 2,496,000 Warrants were issued in connection with the private placement. Each Warrant will entitle the holder to purchase one common share at a price of \$0.08 for a period of 36 months from the closing of the Offering. The fair value of the Company's common shares on closing was \$99,840 with a residual fair value of \$24,960 allocated to the Warrants.

b) Warrants

The Company's warrants outstanding as at September 30, 2023 and December 31, 2022 are as follows:

| | Number of Warrants | Weighted Average Exercise Price |
|-----------------------------|-----------------------|---------------------------------------|
| Balance, December 31, 2021 | 91,427,784 | \$ 0.11 |
| Issued | 14,581,220 | 0.08 |
| Expired | (8,938,890) | 0.13 |
| Balance, December 31, 2022 | 97,070,114 | \$ 0.10 |
| Issued (i) | 2,496,000 | 0.08 |
| Expired | (6,720,500) | 0.10 |
| Balance, September 30, 2023 | 92,845,614 | 0.10 |

(i) On February 28, 2023, 500,000 warrants, previously granted on February 28, 2021, were extended for an additional one year with an amended expiry date of February 28, 2024.

On August 24, 2023, 125,000 warrants, previously granted on August 24, 2020 and previously amended on August 24, 2022, were extended for an additional one year with an amended expiry date of August 24, 2024.

The grant date fair value of the amended warrants was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions:

| | Amended Warrants | Original Warrants |
|------------------------|------------------|--------------------------|
| Grant date share price | \$0.03 - \$0.06 | \$0.08 - \$0.09 |
| Exercise price | \$0.08 - \$0.15 | \$0.08 - \$0.15 |
| Risk free rate | 4.21% - 4.76% | 4.21% - 4.76% |
| Expected life (years) | 1.00 | 0.00 |
| Expected volatility | 120% - 134% | 0% |
| Expected dividends | 0% | 0% |
| Forfeiture rate | 0% | 0% |

The total cost of the warrant amendments is \$9,250 which has been recorded as net financing expense during the nine months ended September 30, 2023.

Notes to Condensed Consolidated Interim Financial Statements For the Three and Nine months Ended September 30, 2023 and 2022

Unaudited - Expressed in Canadian Dollars except otherwise noted

Warrants outstanding as of September 30, 2023 were as follows:

| Expiry Date | Exercise Price | Outstanding Warrants |
|--------------------|----------------|-----------------------------|
| February 28, 2024 | \$0.15 | 500,000 |
| March 1, 2024 | \$0.10 | 45,022,210 |
| August 24, 2024 | \$0.08 | 125,000 |
| November 3, 2024 | \$0.12 | 12,770,341 |
| December 7, 2024 | \$0.12 | 17,350,843 |
| December 20, 2025 | \$0.08 | 14,581,220 |
| September 14, 2026 | \$0.08 | 2,496,000 |
| | \$0.10 | 92,845,614 |

The weighted average remaining contractual life of warrants outstanding as of September 30, 2023 is 1.01 years (December 31, 2022 – 1.56 years).

NOTE 7 - SHARE-BASED PAYMENTS

On February 4, 2013, the Company adopted a "rolling" stock option plan for its employees, directors, officers and self-employed consultants, which plan received regulatory approval in 2013. The terms of the plan provide for options to be granted to a maximum of 10% of the issued and outstanding common shares of the Company at the time of grant of the stock options. The exercise price of each option shall not be less than the minimum price permitted by the policies of the Exchange. The options may be granted for a maximum term of ten years from the date of grant, and at the Board's election, may include vesting provisions. The total amount of share-based payments expense, if any, which is expected to be recognized over the vesting period of options, is recognized during the period in which it occurs.

On October 31, 2018, at the Company's Annual General Meeting the shareholders approved a new stock option plan to incorporate the polices of the Canadian Stock Exchange ("CSE"). Under the new stock option plan the maximum number of shares of the Company reserved for issuance will be limited to 10% of the issued shares of the Company at the time of any granting of options (on a non-diluted basis). In addition, the number of shares which may be reserved for issuance to any one individual may not exceed 5% of the issued shares on a yearly basis or 2% if the optionee is engaged in investor relations activities or is a consultant. The Board may from time to time authorize the issue of options to directors, officers, employees and consultants of the Company and its subsidiaries or employees of companies providing management or consulting services to the Company or its subsidiaries. The exercise price of each option shall be determined by the Board provided that such exercise price shall be not lower than the greater closing price of the Company's shares on the CSE on the trading day prior to the date of grant. The options may be granted for a maximum term of ten years from the date of grant, and at the Board's election, may include vesting provisions. The total amount of share-based payments expense, if any, which is expected to be recognized over the vesting period of options, is recognized during the period in which it occurs.

a) Stock options

The Company's recorded share-based compensation expense for the three and nine months ended September 30, 2023 and 2022 comprised of the following:

| | Three months period ended | | | | Nine m | onth | s period ended |
|---------------|---------------------------|----|---------|----|-----------------------|------|----------------|
| | September 30, 2023 | | | | September 30, 2022 | | |
| Stock Options | \$ 17,600 | \$ | 119,950 | \$ | 236,000 | \$ | 168,042 |

Notes to Condensed Consolidated Interim Financial Statements For the Three and Nine months Ended September 30, 2023 and 2022

Unaudited - Expressed in Canadian Dollars except otherwise noted

Movements in the number of stock options outstanding and their related weighted average exercise prices are as follows:

| | Number of options | Weighted average exercise price |
|-----------------------------|-------------------|---------------------------------|
| Balance, December 31, 2021 | 12,900,000 | \$ 0.10 |
| Granted (i) | 3,300,000 | 0.07 |
| Expired (ii) | (3,600,000) | 0.08 |
| Balance, December 31, 2022 | 12,600,000 | \$ 0.10 |
| Granted (iii) | 6,400,000 | 0.06 |
| Expired (iv) | (6,450,000) | 0.13 |
| Balance, September 30, 2023 | 12,550,000 | \$ 0.06 |

- (i) During the year ended December 31, 2022, the Company granted a total of 3,300,000 incentive stock options with 500,000 granted to an officer of the Company. The remaining 2,800,000 were granted to consultants of the Company. The options have an exercise price of between \$0.065 \$0.07 per common share. The weighted average fair value of stock options granted in the year was estimated at \$0.04 per option.
- (ii) During the year ended December 31, 2022, a total of 3,600,000 stock options expired without exercise resulting in a transfer of \$673,700 from share-based payment reserve to accumulated deficit.
- (iii) During the nine months ended September 30, 2023, the Company granted a total of 6,400,000 (2022 600,000) incentive stock options with 1,500,000 (2022 nil) granted to officers of the Company. The remaining 4,900,000 (2022 600,000) were granted to consultants of the Company. The options have an exercise price of \$0.050 \$0.060 per common share. The weighted average fair value of stock options granted in the year was estimated at \$0.04 per option (2022 \$0.04).
- (iv) During the nine months ended September 30, 2023 a total of 6,450,000 stock options expired without exercise resulting in a transfer of \$412,350 from share-based payment reserve to accumulated deficit.

The Company fair valued the options granted during the nine months ended September 30, 2023 and 2022 using the Black-Scholes option pricing model with the following weighted average inputs:

| | September 30, 2023 | September 30, 2022 |
|------------------------|--------------------|--------------------|
| Grant date share price | \$0.035 - \$0.060 | \$0.05 - \$0.065 |
| Exercise price | \$0.050 - \$0.060 | \$0.065 - \$0.07 |
| Risk free rate | 3.42% - 4.68% | 2.64% - 3.58% |
| Expected life (years) | 2.00 | 2.00 - 2.04 |
| Expected volatility | 130% - 136% | 125% - 133% |
| Expected dividends | 0% | 0% |
| Forfeiture rate | 0% | 0% |

Total fair value of stock options granted for the three and nine months ended September 30, 2023 was \$17,600 and \$236,000 (three and nine months ended September 30, 2022 - \$110,700 and \$126,900) respectively.

Notes to Condensed Consolidated Interim Financial Statements For the Three and Nine months Ended September 30, 2023 and 2022

Unaudited - Expressed in Canadian Dollars except otherwise noted

Stock options outstanding and exercisable as of September 30, 2023 are as follows:

| | Number of Options | | | |
|-------------------------------|-------------------|----------|-------|-------------------|
| Number of Options Outstanding | Exercisable | Exercise | Price | Expiry Date |
| 1,000,000 | 1,000,000 | \$ | 0.065 | October 6, 2023 |
| 1,100,000 | 1,100,000 | \$ | 0.095 | October 19, 2023 |
| 600,000 | 600,000 | \$ | 0.070 | May 31, 2024 |
| 2,700,000 | 2,700,000 | \$ | 0.065 | September 2, 2024 |
| 750,000 | 750,000 | \$ | 0.090 | December 7, 2024 |
| 5,100,000 | 5,100,000 | \$ | 0.060 | March 24, 2025 |
| 500,000 | 500,000 | \$ | 0.060 | March 29, 2025 |
| 800,000 | 800,000 | \$ | 0.050 | September 6, 2025 |
| 12,550,000 | 12,550,000 | \$ | 0.062 | |

The weighted average remaining contractual life of stock options outstanding and exercisable as of September 30, 2023 is 1.09 years (December 31, 2022 - 1.93 years).

NOTE 8 - RELATED PARTY TRANSACTIONS AND BALANCES

Key management personnel compensation

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company defines key management personnel as being the directors and key officers.

The compensation awarded to key management personnel is as follows:

| | Three | Three months ended September 30: | | | | Nine months ended Septembe | | | | |
|----------------------------------|-------|----------------------------------|----|--------|----|----------------------------|----|---------|--|--|
| | | 2023 | | 2022 | | 2023 | | 2022 | | |
| Professional and consulting fees | \$ | 54,000 | \$ | 37,500 | \$ | 162,000 | \$ | 112,500 | | |
| Director fees | | 12,535 | | 9,000 | | 39,535 | | 21,000 | | |
| Share-based payments | | - | | 20,500 | | 58,500 | | 20,500 | | |
| Total compensation | \$ | 66,535 | \$ | 67,000 | \$ | 260,035 | \$ | 154,000 | | |

Other related party transactions

Effective May 1, 2016, the Company entered into an office rental agreement in which an officer and director is a shareholder. The Company was charged rent, office and parking expenses:

| | Т | hree months end | eptember 30: |): Nine months ended September 30 | | | | | | |
|--------------------------|----|-----------------|--------------|-----------------------------------|----|--------|----|--------|--|--|
| | | 2023 | | 2022 | | 2023 | | 2022 | | |
| Rent, office and parking | \$ | 23,049 | \$ | 29,762 | \$ | 69,147 | \$ | 66,777 | | |

Due to related parties

Balances owed to key management personnel and related parties, which are included in accounts payable and accrued liabilities are as follows:

| | September 30, 2023 | December 31, 2022 |
|--------------------------------------|--------------------|-------------------|
| Due to Chief Financial Officer | \$ 164,985 | \$ 44,672 |
| Due to directors | 19,425 | 1,014 |
| Rent, office and parking payable | 38,876 | - |
| Total balance due to related parties | \$ 223,286 | \$ 45,686 |

Notes to Condensed Consolidated Interim Financial Statements For the Three and Nine months Ended September 30, 2023 and 2022

Unaudited - Expressed in Canadian Dollars except otherwise noted

NOTE 9 - FINANCIAL INSTRUMENTS

Fair values

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs in the valuation techniques as follows:

- Level 1 Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3 Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

The carrying values of cash, receivables and advances, share subscriptions receivable, accounts payable and accrued liabilities, and share subscriptions payable approximate their fair values due to the immediate or short-term nature of these instruments. The fair values of loans and borrowings approximate their carrying values due to the market rate of interest being applied. There has been no significant change in credit and market interest rates since the date of its receipt.

Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Change in assumptions could significantly affect the estimates.

The following table summarizes the classification of the Company's financial instruments under IFRS 9 – Financial Instruments:

| Amortized cost |
|----------------------------------|
| Amortized cost |
| Amortized cost |
| |
| Amortized cost |
| Amortized cost Amortized cost |
| |

Capital and risk management

The Company's objective and polices for managing capital are to safeguard its ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital. The Company manages its capital structure and makes changes based on economic conditions, risks that impact the operations and future significant capital investment opportunities. In order to maintain or adjust its capital structure, the Company may issue new equity instruments or raise additional debt financing.

The Company is exposed to a variety of financial risks by virtue of its activities: market risk, interest rate risk, liquidity risk and foreign currency risk. The Board of Directors has overall responsibility for the determination of the Company's capital and risk management objectives and policies while retaining ultimate responsibility for them. The Company's overall capital and risk management program has not changed throughout the period. It focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on financial performance. Risk management is carried out by the finance department under policies approved by the Board of Directors. The finance department identifies and evaluates financial risks in close cooperation with management.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's interest-bearing debt instrument has a fixed interest rate and is not subject to interest rate cash flow risk.

Notes to Condensed Consolidated Interim Financial Statements For the Three and Nine months Ended September 30, 2023 and 2022

Unaudited - Expressed in Canadian Dollars except otherwise noted

The interest-bearing financial instruments, as reported in the consolidated financial statements, have the following interest rate profile:

| As at: | September 30, 2023 | December 31, 2022 |
|------------------------|---------------------------|-------------------|
| Fixed rate instruments | \$ 65,562 | \$ 60,133 |

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company generally relies on external financing or key management to provide sufficient liquidity to meet budgeted operating requirements. The following table sets forth details of the payment profile of financial liabilities based on their undiscounted cash flows:

| | Total carrying amount | Contractual cash flows | Less than 1 year | 1 to 5 years | More than 5 years |
|--|-----------------------|------------------------|---------------------|-----------------|-------------------------|
| Accounts payable and accrued liabilities | \$ 1,220,555 | \$ 1,220,555 | \$ 1,220,555 | \$ - | \$ - |
| Loans and borrowings | 65,562 | 65,562 | 65,562 | - | - |
| Share subscriptions payable | 10,000 | 10,000 | 10,000 | | |
| Totals | \$ 1,296,117 | \$ 1,296,117 | \$ 1,296,117 | \$ - | \$ - |

Taking into consideration the Company's current cash position, volatile equity markets, global uncertainty in the capital markets and increasing cost pressures, the Company is continuing to review its needs to seek financing opportunities in accordance to its capital risk management strategy.

Foreign currency risk

Foreign currency risk is defined as the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company maintains financial instruments and enters into transactions denominated in foreign currencies, principally in U.S. dollar, which exposes the Company to fluctuating balances and cash flows due to various in foreign exchange rates.

NOTE 10 - SEGMENT REPORTING

All of the Company's operations are based in Canada.

NOTE 11 - EVENTS AFTER REPORTING PERIOD

- On October 20, 2023, the Company closed an unsecured term loan in the amount of \$15,000 with bonus warrants. The
 Term Loan matures on January 31, 2024, and has an interest rate of 8% per annum. The bonus warrants consist of
 300,000 share purchase warrants which will entitle the holder thereof to purchase 300,000 common shares of the
 Company at a price of \$0.05 for a period of 24 months from the close of the Term Loan.
- On October 23, 2023, the Company granted 2,000,000 incentive stock options at an exercise price of \$0.05 per common share. The stock options are fully vested and are exercisable on or before October 23, 2025.
- On November 15, 2023, the Company granted 600,000 incentive stock options at an exercise price of \$0.05 per common share. The stock options vest in 200,000 tranches ever ninety (90) days and are exercisable on or before November 15, 2026.